-
Whats the Durability of Lifestyle Change in Type 2 Diabetes?; Perimenstrual Asthma: A High-Risk Phenotype; Risk of New Onset Diabetes with Statins
-
A strategy of annual screening of blood pressure was as sensitive and more specific than the usual practice of measuring it at every office visit.
-
Bacteria were present on the cell phones of all hospital clinicians studied, with potentially pathogenic microorganisms isolated from 29% of them. Contamination with pathogens was found more commonly with smart phones than with non-smart phones, and by multivariable analysis no other factor was associated with this difference.
-
A brief web intervention improved shared decision making regarding prostate cancer screening.
-
Once-daily Tadalafil for ED: Efficacy and Safety; Psychological Disorders: How to Give Patients What They Want and What They Need; Reducing Stroke Risk After TIA or Minor Ischemic Stroke
-
Digoxin has no association with mortality in patients with heart failure in the AFFIRM study when bias is removed with a careful propensity-matched analysis.
-
The authors compared potential risk factors, clini-cal symptoms, diagnostic delay, and 3-month outcome between spontaneous internal carotid artery dissection (sICAD) and spontaneous vertebral artery dissection (sVAD).
-
In patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity.
-
The impression is acute infero-posterior infarction, with possible lateral and right ventricular involvement. In most patients, the right coronary artery (RCA) supplies the right ventricle and posterior and inferior walls of the left ventricle.
-
The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon.
